ArticleGene therapy2014
CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging.
Article in Gene therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 41 citations in OpenAlex.
- Vaccinia Virus-A Swiss Army Knife Against Cancer.Cancers · 2025Review
- Oncolytic vaccinia virus and cancer immunotherapy.Frontiers in immunology · 2023Review
- Current strategies in engaging oncolytic viruses with antitumor immunity.Molecular therapy oncolytics · 2021Review
- Oncolytic Adenovirus Type 3 Coding for CD40L Facilitates Dendritic Cell Therapy of Prostate Cancer in Humanized Mice and Patient Samples.Human gene therapy · 2021Article
- Deletion of Apoptosis Inhibitor F1L in Vaccinia Virus Increases Safety and Oncolysis for Cancer Therapy.Molecular therapy oncolytics · 2019Article
- Armed oncolytic viruses: A kick-start for anti-tumor immunity.Cytokine & growth factor reviews · 2018Review
- A Fast and Inexpensive Protocol for Empirical Verification of Neutralizing Epitopes in Microbial Toxins and Enzymes.Frontiers in veterinary science · 2017Article
- The importance of imaging strategies for pre-clinical and clinical in vivo distribution of oncolytic viruses.Oncolytic virotherapy · 2017Review
- Recombinant Vaccinia Viruses Coding Transgenes of Apoptosis-Inducing Proteins Enhance Apoptosis But Not Immunogenicity of Infected Tumor Cells.BioMed research international · 2017Article
- Colonization of xenograft tumors by oncolytic vaccinia virus (VACV) results in enhanced tumor killing due to the involvement of myeloid cells.Journal of translational medicine · 2016Article
- From Benchtop to Bedside: A Review of Oncolytic Virotherapy.Biomedicines · 2016Review
- Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer.Oncotarget · 2016Article
- Trial Watch-Oncolytic viruses and cancer therapy.Oncoimmunology · 2016Review
- Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity.Molecular therapy oncolytics · 2016Article
- Targeted therapies in bladder cancer: an overview of in vivo research.Nature reviews. Urology · 2015Review
- The evolution of poxvirus vaccines.Viruses · 2015Review
- Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy.Molecular therapy oncolytics · 2015Article
- Incomplete but infectious vaccinia virions are produced in the absence of oncolysis in feline SCCF1 cells.PloS one · 2015Article
- Enhancing poxvirus vectors vaccine immunogenicity.Human vaccines & immunotherapeutics · 2014Review
- Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer.Molecular therapy oncolytics · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncolytic vaccinia virus is an attractive platform for immunotherapy. Oncolysis releases tumor antigens and provides co-stimulatory danger signals. However, arming the virus can improve efficacy further. CD40 ligand (CD40L, CD154) can induce apoptosis of tumor cells and it also triggers several immune mechanisms. One of these is a T-helper type 1 (Th1) response that leads to activation of cytotoxic T-cells and reduction of immune suppression. Therefore, we constructed an oncolytic vaccinia virus expressing hCD40L (vvdd-hCD40L-tdTomato), which in addition features a cDNA expressing the tdTomato fluorochrome for detection of virus, potentially important for biosafety evaluation. We show effective expression of functional CD40L both in vitro and in vivo. In a xenograft model of bladder carcinoma sensitive to CD40L treatment, we show that growth of tumors was significantly inhibited by the oncolysis and apoptosis following both intravenous and intratumoral administration. In a CD40-negative model, CD40L expression did not add potency to vaccinia oncolysis. Tumors treated with vvdd-mCD40L-tdtomato showed enhanced efficacy in a syngenic mouse model and induced recruitment of antigen-presenting cells and lymphocytes at the tumor site. In summary, oncolytic vaccinia virus coding for CD40L mediates multiple antitumor effects including oncolysis, apoptosis and induction of Th1 type T-cell responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.